I
Index Pharmaceuticals
Developing drugs to treat inflammatory bowel disease that can help patients return to a normal life
About Index Pharmaceuticals
InDex Pharmaceuticals Holding AB is a biopharmaceutical company listed on the Nasdaq First North Growth Market. The company focuses on developing innovative treatments for immunological disorders, with a particular emphasis on ulcerative colitis, a chronic inflammatory bowel disease. The Group includes InDex Pharmaceuticals AB and its wholly-owned subsidiary, InDex Diagnostics AB.
Read full description
The primary product in InDex Pharmaceuticals' pipeline is cobitolimod, a drug designed to treat moderate to severe left-sided ulcerative colitis. Cobitolimod has a unique mechanism of action, which aims to provide effective and safe treatment options for patients who have limited alternatives. The company is currently preparing for a Phase III clinical trial to further evaluate the drug's efficacy and safety.
InDex Pharmaceuticals serves patients suffering from immunological disorders, particularly those with ulcerative colitis. The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs based on biological sources.
The business model of InDex Pharmaceuticals revolves around research and development (R&D) of new drug candidates. The company invests heavily in clinical trials to ensure the safety and efficacy of its products. Revenue is generated through the successful commercialization of these drugs, either by bringing them to market directly or through partnerships and licensing agreements with larger pharmaceutical companies.
InDex Pharmaceuticals makes money by advancing its drug candidates through the clinical trial phases and eventually obtaining regulatory approval for market release. Once approved, the company can either sell the drugs directly to healthcare providers and patients or license the rights to other pharmaceutical companies in exchange for royalties and milestone payments.
At a glance
- Status
- Operational
- Founded
- 2000
- Headquarters
- Solna kommun, Sweden
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 57.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Gastroenterology, Genetics and genomics, Immune System, Spinout, Sustainable Development Goals, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2020 | $242K | — | Vinnova | — |
| GRANT✓Other financing | Mar 2018 | $55K | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Index Pharmaceuticals is 1.3K monthly website visits, down 67.5% over the last three months. Index Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 XenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform |
Nantes, France | Operational | 22 | $29M | $88M |
 Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming |
Lund Municipality, Sweden | Operational | |||
 AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
 Blueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases |
Espoo, Finland | Operational | |||
 BioNTechDevelops personalized immunotherapies with a focus on cancer medicine |
Mainz, Germany | Operational | |||
 Scenic BiotechGenetic modifier therapies for rare inherited diseases |
Amsterdam, Netherlands | Operational | |||
 ScancellClinical-stage immunotherapies for difficult-to-treat cancers |
Oxford, United Kingdom | Operational | |||
 Oryzon GenomicsDevelops diagnostic and therapeutic tools |
Cornellà de Llobregat, Spain | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Vinnova
European Innovation Council
Series A3 investors entered at this stage
Industrifonden
SEB Venture Capital
NeoMed
Other known investors2 additional known investors
Karolinska Institute
KI Science Park
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Index Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Index Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.